The new patent covers methods for determining the presence or absence of a fetal aneuploidy, or an abnormal number of fetal chromosomes, by analysis of blood samples from pregnant women.
Verinata Health CEO Caren Mason said that they are pleased that the USPTO has recognized this invention from Quake laboratory at Stanford that provides foundation for their prenatal diagnostic test.